Transition state analogue discrimination by related purine nucleoside phosphorylases

Journal of the American Chemical Society

Volumn 128, Issue 22, 2006, Pages 7126-7127

  Taylor Ringia, Erika A ^a   Tyler, Peter C ^b   Evans, Gary B ^b   Furneaux, Richard H ^b   Murkin, Andrew S ^a   Schramm, Vern L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CALLAGHAN INNOVATION   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUCILLIN H; PURINE NUCLEOSIDE PHOSPHORYLASE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR;

ARTICLE; CATABOLISM; CATALYSIS; COW; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PHASE TRANSITION; RECYCLING;

ANIMALS; ARSENATES; CATTLE; ENZYME INHIBITORS; ERYTHROCYTES; HUMANS; MICE; MOLECULAR STRUCTURE; PROTEIN BINDING; PURINE NUCLEOSIDES; PURINE-NUCLEOSIDE PHOSPHORYLASE; PYRIMIDINONES; PYRROLIDINES;

EID: 33744907483     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja061403n     Document Type: Article

References (20)

1. Stoeckler, J. D. Purine Nucleoside Phosphorylase: A Target for Chemotherapy. In Developments in Cancer Chemotherapy; Glazer, R. J., Ed.; CRC Press: Boca Raton, FL, 1984; pp 35-60.
2. Bantia, S.; Kilpatrick, J. M. Curr. Opin. Drug Discovery Dev. 2004, 7, 243-247.
3. (a) Schramm, V. L. Methods Enzymol. 1999, 308, 301-355.
4. (b) Schramm, V. L. Acc. Chem. Res. 2003, 36, 588-596.
5. (c) Wolfenden, R. Annu. Rev. Biophys. Bioeng. 1976, 5, 271-306.
6. Rodgers, J.; Femec, D. A.; Schowen, R. L. J. Am. Chem. Soc. 1982, 104, 3263-3268.
7. Cleland, W. W. Methods Enzymol. 1982, 87, 625-641.
8. Berti, P. J. Methods Enzymol. 1999, 307, 355-397.
9. Kline, P. C.; Schramm, V. L. Biochemistry 1993, 32, 13212-13219.
10. Lewandowicz, A.; Schramm, V. L. Biochemistry 2004, 43, 1458-1468.
11. Furneaux, R. H.; Tyler, P. C. J. Org. Chem. 1999, 64, 8411-8412.
12. Miles, R. W.; Tyler, P. C.; Furneaux, R. H.; Bagdassarian, C. K.; Schramm, V. L. Biochemistry 1998, 37, 8615-8621.
13. Evans, G. B.; Furneaux, R. H.; Lewandowicz, A.; Schramm, V. L.; Tyler, P. C. J. Med. Chem. 2003, 46, 5271-5276.
14. The arsenate, which is only found in van der Waals contact with the ribose in both transition states, was not displayed for simplicity of visualizing the ribose base geometry changes between the two enzymes.
15. Inhibition constants are reported from the indicated literature value with the least error. If no reference is given for a value, it is previously unreported. Dissociation constants represent values corresponding to slow-onset, tight-binding inhibition, except for compound 7 for HsPNP and compounds 7 and 8 for BtPNP. Values shown here are final equilibrium dissociation constants.
16. Evans, G. B.; Furneaux, R. H.; Lewandowicz, A.; Schramm, V. L.; Tyler, P. C. J. Med. Chem. 2003, 46, 3412-3423.
17. Lewandowicz, A.; Taylor Ringia, E. A.; Ting, L.-M.; Kim, K.; Tyler, P. C.; Evans, G. B.; Zubkova, O. V.; Mee, S.; Painter, G. P.; Lenz, D. H.; Furneaux, R. H.; Schramm, V. L. J. Biol. Chem. 2005, 280, 30320-30328.
18. Lewandowicz, A.; Tyler, P. C.; Evans, G. B.; Schramm, V. L. J. Biol. Chem. 2003, 278, 31465-31468.
19. Fedorov, A.; Shi, W.; Kicska, G.; Fedorov, E.; Tyler, P. C.; Furneaux, R. H.; Hanson, J. C.; Gainsford, G. J.; Larese, J. Z.; Schramm, V. L.; Almo, S. C. Biochemistry 2001, 40, 853-860.
20. Shi, W.; Lewandowicz, A.; Tyler, P. C.; Furneaux, R. H.; Almo, S. C.; Schramm, V. L. Unpublished data (pdb file name 1RT9).